Nasdaq ardx.

Force Index charts of Daily price volume action, Weekly price volume action, Monthly price volume action of Ardelyx, Inc. ARDX NASDAQ. Data to use: Daily ...Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...May 18, 2023 · Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...

Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...

Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that designs and sells treatments for gastrointestinal, heart, and kidney diseases. These include irritable bowel syndrome, chronic ...ARDX Ardelyx NASDAQ 4.330 +0.300 +7.44% After Hours: 4.430 +0.1 +2.31% 19:59 11/17 EST OPEN 4.030 PREV CLOSE 4.030 HIGH 4.450 LOW 4.010 VOLUME 7.35M …

Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...In the latest trading session, Ardelyx (ARDX) closed at $3.02, marking a -1.63% move from the previous day. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added ...Discover historical prices for ARDX stock on Yahoo Finance. View daily, weekly or monthly format back to when Ardelyx, Inc. stock was issued.Ardelyx Inc. ARDX Ardelyx has made significant strides with its launch of Ibsrela for irritable bowel syndrome in the U.S. and the subsequent Food and Drug Administration (FDA) approval of Xphozah ...

Discover historical prices for ARDX stock on Yahoo Finance. View daily, weekly or monthly format back to when Ardelyx, Inc. stock was issued.

ARDX STOCK Price - Ardelyx Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.

Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...14 thg 9, 2023 ... Fintel reports that on September 13, 2023, Wedbush reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Outperform recommendation.Ardelyx Inc. ARDX (U.S.: Nasdaq). AT CLOSE 4:00 PM EST 12/01/23. $4.76USD; 0.25 ... ARDX. Significant News Only. 11/17/22; Barron's. Ardelyx Skyrockets. Its ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ...

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx’s financial performance into perspective. NASDAQ: ARDX. $4.76. …WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ...Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …May 17, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... 16 thg 8, 2021 ... Ardelyx (NASDAQ:ARDX) is trading higher today on below-average volume despite a loss of over 5% on Friday after the company announced worse ...

Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […] Oct 11, 2023 · Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...

Ardelyx, Inc. (NASDAQ:ARDX) shares have gained about 47% year to date through August 10. Ardelyx, Inc. (NASDAQ:ARDX) recently posted Q2 results. GAAP EPS in the quarter came in at -$0.08 beating ...Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.5 equities research analysts have issued 12-month price targets for Ardelyx's shares. Their ARDX share price targets range from $7.00 to $11.00. On average, ...ARDX U.S.: Nasdaq Ardelyx Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 4:07 p.m. EST Real time quote $ 4.7615 0.00 0.03% After Hours Volume: 89.07K...Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...

Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...

Ardelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...The restructuring drive implemented on August 02 is intended “to reduce operating costs and better align the Company’s workforce with the needs of its business,” Ardelyx (NASDAQ:ARDX) said ...WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended …WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, …Ardelyx (NASDAQ: ARDX) is a biotechnology company that creates medicines for currently unmet medical needs. ARDX stock is up 34.33% YTD. Analysts rate the stock from a “buy” to a “strong buy ...31 thg 8, 2023 ... The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 8.59 / share. This is an increase of 18.82% from the prior ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Nov 24, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...13 thg 9, 2023 ... Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation.Instagram:https://instagram. fidelity u.s. bond index fundspacex valuation 2023big sur coastlinetop etf emerging markets The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 81.50% from its latest reported closing price of 4.73. leaderboard of companies with ... farmers small business insurancebno etf Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.Mar 3, 2023 · On March 3, 2023, Wedbush upgraded their outlook for Ardelyx (NASDAQ:ARDX) from Neutral to Outperform.. Analyst Price Forecast Suggests 47.30% Upside. As of March 4, 2023, the average one-year ... books day trading WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...16 thg 8, 2021 ... Ardelyx (NASDAQ:ARDX) is trading higher today on below-average volume despite a loss of over 5% on Friday after the company announced worse ...